Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Targeted therapy ivosidenib shows clinical benefit in cholangiocarcinoma

ESMO 2019

27 Sep - 1 Oct 2019

Published: 30 Sep 2019

Views: 1150

Rating:

Save

Prof Ghassan Abou-Alfa - Memorial Sloan Kettering Cancer Center, New York City, USA

Prof Ghassan Abou-Alfa presents data from the ClarIDHy trial during a press conference at the 2019 ESMO congress.

This was a phase III trial evaluating the use of the targeted therapy ivosidenib for advanced cholagiocarcinoma patients with the isocitrate dehydrogenase 1 (IDH1) mutation.

Watch Prof Abou-Alfa's interview with ecancer here.

Watch Dr Angela Lamarca's comment here.

Read more about the study here.

Related Videos

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

ASCO 2024: Lung cancer highlights

Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom

ASCO 2024: Lung cancer highlights ( Dr Antonio Passaro, Dr Matthew Krebs, Prof Raffaele Califano, Prof Nicolas Girard and Dr Anna Minchom )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib shows clinically meaningful improvement in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer